School age outcome of hospitalisation with respiratory syncytial virus infection of prematurely born infants

A Greenough,1 J Alexander,2 P Boit,2 J Boorman,3 S Burgess,4 A Burke,5 P A Chetcuti,4 I Cliff,2 W Lenney,2 T Lytle,3 C Morgan,5 C Raiman,1 N J Shaw,5 K P Sylvester,1 J Turner6

ABSTRACT

Background: Hospitalisation due to respiratory syncytial virus (RSV) infection in the first 2 years after birth has been associated with increased healthcare utilisation and associated costs up to 5 years of age in children born prematurely at less than 32 weeks of gestation who developed bronchopulmonary dysplasia (BPD). A study was undertaken to determine whether hospitalisation due to RSV infection in the first 2 years was associated with increased morbidity and lung function abnormalities in such children at school age, and if any effects were influenced by age.

Methods: Healthcare utilisation and cost of care in years 5–7 were reviewed in 147 children and changes in healthcare utilisation between 0 and 8 years were assessed also using results from two previous studies. At age 8–10 years, 77 children had their lung function assessed and bronchial hyper-responsiveness determined.

Results: Children hospitalised with RSV infection (n = 25) in the first 2 years had a greater cost of care related to outpatient attendance than those with a non-respiratory or no admission (n = 72) when aged 5–7 years (p = 0.008). At 8–10 years of age, children hospitalised with RSV infection (n = 14) had lower forced expiratory volume in 0.75 s (FEV0.75) (p = 0.015), FEV0.75/forced vital capacity (p = 0.027) and flows at 50% (p = 0.034) and 75% (p = 0.006) of vital capacity than children hospitalised for non-RSV causes (n = 63). Healthcare utilisation decreased with increasing age regardless of RSV hospitalisation status.

Conclusions: In prematurely born children who had BPD, hospitalisation due to RSV infection in the first 2 years is associated with reduced airway calibre at school age.

Respiratory syncytial virus (RSV) infection in previously healthy term-born infants is associated with increased respiratory problems at follow-up.1–3 Chronic respiratory morbidity also appears to be increased in prematurely born infants following symptomatic RSV infection.4–6 Prematurely born infants with or without bronchopulmonary dysplasia (BPD) who had an RSV lower respiratory tract infection had more days of cough and wheeze at follow-up at 1 year of corrected age.1 In addition, following hospitalisation for RSV infection in the first 2 years, healthcare utilisation was increased up to 2 years of age and in years 2–4 inclusive in prematurely born children with BPD. We have now re-examined our BPD cohort with regard to their healthcare utilisation and associated cost of care between years 5 and 7 inclusive and assessed their lung function. Our aims were to determine whether, at school age, prematurely born children who had been hospitalised with an RSV infection in the first 2 years after birth still had an excess morbidity and whether this was associated with reduced lung function. In addition, by also examining the earlier results from the BPD cohort,3–6 we wished to determine if any effects on healthcare utilisation were influenced by age.

METHODS

The cohort consisted of children born at less than 32 weeks of gestation admitted during the first week after birth to one of four neonatal intensive care units who developed BPD.3–6 For this study, the parents were approached when their child was at least 8 years of age and, if they gave informed written consent, review was made of hospital admissions and community care when the children were aged 5–7 years inclusive and the associated cost of care calculated. Parents were asked to complete respiratory and health-related quality of life questionnaires regarding their child and to consent to their child undertaking lung function and skin prick testing.

Measurements

Healthcare utilisation and cost of care

Healthcare utilisation was assessed as previously described.3–6 The mean costs of each admission and outpatient attendance were calculated using data from the National Scheme of Reference Costs (2003) and medication costs from the British National Formulary prices. All primary care costs were those reported by Netten et al.7

Respiratory questionnaire

Questions were asked regarding known risk factors for respiratory morbidity. A family history of atopy was diagnosed if a parent or sibling had asthma, eczema and/or hay fever.

Lung function testing

This was undertaken in the four centres with standardisation between them. No child was tested within 2 weeks of an upper respiratory tract infection. Short-acting bronchodilators were withheld from midnight on the previous day if possible, but always at least 4 h before testing. At baseline, forced expiratory volume in 0.75 s (FEV0.75), forced vital capacity (FVC), forced expiratory flow (FEF)
(measured from the top of the breath $FEV_{25}$ is the flow at 75%; $FEF_{50}$ is the flow at 50%; $FEF_{25}$ at 25% of the vital capacity) and peak expiratory flow (PEF) were measured using a Lilley pneumotachograph (Vitalograph 2120, Vitalograph, Buckingham, UK). $FEV_{0.75}/FVC$ was calculated from the results. The lung function results were expressed as percentage predicted for height. 

Bronchial challenges were then performed. If the subject’s $FEV_{0.75}$ was more than 80% of that predicted, a cold air challenge was performed, but if <80%, a bronchodilator challenge was performed. For the cold air challenge, subfreezing ($-15^\circ$C) gas (5% carbon dioxide, balance air) was inhaled for 4 min. Measurements of $FEV_{0.75}$ were carried out every 2 min for a maximum of 12 min after the cold air challenge. A result was considered positive if, at any point, the maximum $FEV_{0.75}$ fell by 12% from the maximum pre-challenge baseline. For the bronchodilator challenge, 100 μg salbutamol (twice) was delivered. $FEV_{0.75}$ was remeasured 20 min after the bronchodilator and a result was considered positive in there was an increase from baseline of at least 15%.

Skin prick testing
Sensitisation to six common allergens (dog hair, cat hair, house dust mite, six grass mix, tree mix and mould) was assessed. Children were defined as atopic if they had a positive reaction to at least one allergen.

Health-related quality of life
Parents were sent the Health Utilities Index (HUI 2 and 3) and asked to complete the 15 questions to reflect their child’s health over the previous 4 weeks. 

Analysis of data
Only results from children who had taken part in our two previous studies and this follow-up at school age were included. The children were divided into three groups according to admission diagnosis in the first 2 years: (1) RSV; (2) other respiratory; and (3) non-respiratory (non-respiratory/no admission). The RSV group had at least one hospital admission with a proven RSV infection (RSV antigen identified on a nasopharyngeal aspirate (NPA)). Children in the other respiratory group had an admission with probable bronchiolitis (clinical diagnosis but the NPA was negative or no result available) or another respiratory problem (chest infection, croup, apnoea, asthma, wheeze, pneumonia, upper respiratory tract infection, dyspnoea and/or overnight oxygen saturation monitoring). Missing data were not imputed. Comparisons were also made between children with proven RSV infection and the others as indicated. To determine if there were statistically significant differences between groups for categorical data, differences were assessed using the Fisher exact test or $\chi^2$ test as appropriate and a hierarchical analysis was performed on continuous data. The groups were compared using the Kruskal-Wallis test. Only if there was a significant difference of at least $p < 0.10$ was the RSV group compared with each of the other two groups using the two degrees of freedom to perform the two pairwise comparisons. Within each group, the variation with age was analysed using the two-way analysis of variance on ranks with main effects, patients and age. Where a significant difference was found, it was investigated within the ANOVA using a Bonferroni correction. The group by age interaction was examined to determine whether the change over time differed between groups.

RESULTS
The original study included 235 infants. Written informed consent for their child to participate in this study was obtained from 160 parents. Thirteen children who took part in this school age follow-up had not participated in the second study, hence their results were not included (see online appendix, fig 1). None had received RSV immunoprophylaxis.

A total of 147 children took part in the previous studies and in this school age study (ie, complete follow-up data). The demographics of the children who had complete follow-up data differed from those who did not only in that fewer had received surfactant (p = 0.012) (see online appendix 1). The 77 children who underwent lung function testing differed significantly in their demographics from the other 70 children who had complete follow-up data only in that more had received continuous positive airway pressure (p = 0.003, see online appendix 2).

There were no significant differences in the demographics according to hospitalisation status in the first 2 years between the groups (table 1). In years 5–7 neither the hospital admission rate nor the number of GP visits differed significantly between the RSV group and the other two groups, but the RSV group had more outpatient visits than the non-respiratory group (p = 0.007, table 2). Overall, there were no significant differences in the cost of care for hospital stay, GP visits or prescriptions between the RSV group and the other two groups. The cost of outpatient attendances (p = 0.008) was significantly higher and the total cost of care tended to be higher (p = 0.05) in the RSV group than in the non-respiratory group (table 3). The total cost of care (p = 0.04) and the costs for prescriptions (p = 0.05) and hospital admissions (p = 0.02) were higher in the other respiratory groups than in the non-respiratory group (table 3). The total respiratory cost of care differed significantly between the other respiratory and non-respiratory groups (p = 0.004, see online appendix 3).

Data from the respiratory questionnaire demonstrated a trend for more of the RSV group than the rest of the cohort who completed the questionnaire to have a family history of eczema (p = 0.051) and fewer to have wheeze ever (p = 0.045); otherwise, there were no significant differences between the groups.
groups (table 4). Similar results (data not shown) were found for the children who underwent lung function testing.

The median HUI 2 and HUI 3 scores of the RSV group did not differ significantly from those of the other respiratory or non-respiratory groups (data not shown).

Lung function measurements were undertaken in 77 children. The 14 children in the RSV group had similar antenatal/ neonatal demographic characteristics to the rest of the cohort who had lung function testing (non-RSV, table 5) and to the other respiratory and non-respiratory groups (table 6). The RSV group had significantly lower baseline mean FEV0.75, FEV0.75/FVC, mid forced expiratory flow (FEF50) and end forced expiratory flow (FEF75) to the non-RSV group (table 5). Comparison of the three groups showed that the baseline FEV0.75 (p = 0.018), FEV0.75/FVC (p = 0.021) and FEF50 (p = 0.036) of the RSV group were significantly lower than the non-respiratory group; the FEV0.75 of the RSV group was lower than both the other respiratory (p = 0.042) and the non-respiratory (p = 0.018) groups and the FEF75 of the RSV group was also lower than both the other respiratory (p = 0.030) and the non-respiratory (p = 0.005) groups (table 6). There were no significant differences between the three groups with regard to their median peak expiratory flow (PEF), FVC and FEF25 (table 6).

Twenty-nine children underwent a cold air challenge and 65 undertook a bronchodilator challenge (28 after a cold air challenge). None of the four in the RSV group and seven of the 25 in the non-RSV group had a positive response to cold air challenge). None of the four in the RSV group and seven of the 25 in the non-RSV group had a positive response to cold air challenge. Twenty-nine children underwent a cold air challenge and 65 undertook a bronchodilator challenge (28 after a cold air challenge). None of the four in the RSV group and seven of the 25 in the non-RSV group had a positive response to cold air challenge. Twenty-nine children underwent a cold air challenge and 65 undertook a bronchodilator challenge (28 after a cold air challenge). None of the four in the RSV group and seven of the 25 in the non-RSV group had a positive response to cold air challenge.
was the proportion receiving surfactant. In addition, the only significant difference in the demographics of children who did and did not take part in the lung function testing was the proportion who received CPAP. We therefore feel our results are generalisable to prematurely born children with BPD.

The present healthcare utilisation results are consistent with our previous findings in that the children with early hospitalisation due to RSV had more outpatient attendances

Table 4 Results of the respiratory questionnaire by hospital admission status in the first 2 years

<table>
<thead>
<tr>
<th>RSV (n = 17)</th>
<th>Other respiratory (n = 49)</th>
<th>Non-respiratory (n = 63)</th>
<th>p Value between the three groups</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maternal smoking</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>In pregnancy</td>
<td>18%</td>
<td>23%</td>
<td>24%</td>
</tr>
<tr>
<td>Currently</td>
<td>18%</td>
<td>25%</td>
<td>16%</td>
</tr>
<tr>
<td>Breast fed</td>
<td>71%</td>
<td>51%</td>
<td>49%</td>
</tr>
<tr>
<td>Family history</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asthma</td>
<td>38%</td>
<td>33%</td>
<td>33%</td>
</tr>
<tr>
<td>Eczema*</td>
<td>50%*</td>
<td>28%</td>
<td>25%</td>
</tr>
<tr>
<td>Hay fever</td>
<td>53%</td>
<td>36%</td>
<td>47%</td>
</tr>
<tr>
<td>Long haired pets</td>
<td>35%</td>
<td>29%</td>
<td>33%</td>
</tr>
<tr>
<td>Parents homeowners</td>
<td>88%</td>
<td>79%</td>
<td>81%</td>
</tr>
<tr>
<td>Home oxygen</td>
<td>6%</td>
<td>8%</td>
<td>0%</td>
</tr>
<tr>
<td>Cough</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ever</td>
<td>47%</td>
<td>50%</td>
<td>58%</td>
</tr>
<tr>
<td>More than once a week</td>
<td>12%</td>
<td>23%</td>
<td>12%</td>
</tr>
<tr>
<td>Wheeze</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ever</td>
<td>12%</td>
<td>48%</td>
<td>29%</td>
</tr>
<tr>
<td>More than once a week</td>
<td>0%</td>
<td>8%</td>
<td>0%</td>
</tr>
<tr>
<td>Use of medication</td>
<td>12%</td>
<td>33%</td>
<td>15%</td>
</tr>
</tbody>
</table>

*Only 16 in the RSV group answered the questionnaire about eczema.

RSV, respiratory syncytial virus.

Table 5 Baseline lung function results by RSV hospital admission status in the first 2 years

<table>
<thead>
<tr>
<th>RSV group (n = 14)</th>
<th>Non-RSV group (n = 63)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gestational age (weeks)</td>
<td>26 (24–31)</td>
<td>28 (24–31)</td>
</tr>
<tr>
<td>Birth weight (g)</td>
<td>820 (650–1826)</td>
<td>964 (515–1520)</td>
</tr>
<tr>
<td>Maternal steroids (%)</td>
<td>85</td>
<td>82</td>
</tr>
<tr>
<td>Surfactant (%)</td>
<td>86</td>
<td>81</td>
</tr>
<tr>
<td>IPPV (%)</td>
<td>100</td>
<td>97</td>
</tr>
<tr>
<td>CPAP (%)</td>
<td>86</td>
<td>68</td>
</tr>
<tr>
<td>HFOV (%)</td>
<td>8</td>
<td>5</td>
</tr>
<tr>
<td>Nitric oxide (%)</td>
<td>7</td>
<td>7</td>
</tr>
<tr>
<td>PDA (%)</td>
<td>29</td>
<td>37</td>
</tr>
<tr>
<td>Air leak (%)</td>
<td>14</td>
<td>14</td>
</tr>
<tr>
<td>Postnatal dexamethasone (%)</td>
<td>36</td>
<td>38</td>
</tr>
</tbody>
</table>

*Results are expressed as percentage predicted for height.

CPAP, continuous positive airway pressure; FEF, forced expiratory flow; FEF25, flow at 25% of vital capacity; FEF25, flow at 50% of vital capacity; FEF75, flow at 75% of vital capacity; FV, forced expiratory volume; HFOV, high frequency oscillatory ventilation; IPPV, intermittent positive pressure ventilation; PDA, patent ductus arteriosus; PEF, peak expiratory flow; RSV, respiratory syncytial virus.

and a greater associated cost of care. In years 2–4, however, the RSV group also had significantly greater overall cost of care and worse health-related quality of life, suggesting they had suffered greater morbidity at the younger age. It is possible that those we could not follow had been more severely affected, but they had similar antenatal/neonatal demographics to those who were followed. An alternative explanation is that any effect of RSV infection on chronic morbidity in prematurely born children diminishes with increasing age, which is consistent with the results of some studies of children born at term. In one cohort the prevalence of respiratory symptoms, although remaining significantly higher in the RSV group, was lower when the children were 9–10 years of age than when previously reviewed and, in another, although RSV lower respiratory tract infections were associated with an increased risk of infrequent and frequent wheeze at 6 years of age, the risk markedly decreased with increasing age and was not significant at age 13. In another study, however, even at 13 years of age asthma/recurrent wheezing was still markedly higher in the RSV group (45% vs 8%). In addition, in the RSV group, sensitisation to common inhaled allergens was more common. In contrast, other studies have reported no excess of wheezing at 10 years of age and no significant differences in the rates of asthma or allergic sensitisation after 18–20 years. It is possible that these differences may relate to whether hospitalisation was required for the RSV lower respiratory tract infection, age at admission and/or the allergen load.

Healthcare utilisation decreased significantly with increasing postnatal age in all three groups in this study, yet there were significant differences between the RSV group and the non-respiratory group at the age of 5–7 years. Whether early RSV infection impacts adversely on prematurely born children when they are adolescents requires investigation.

Both the RSV and non-RSV group had lung function results on average below that predicted for their height, consistent with our study population being born very prematurely and having had BPD. Nevertheless, the RSV group had significantly worse lung function than those without previous hospitalisation for RSV infection. The RSV group had significantly lower PEF, FEF25, FEF50 and FEF75, indicating...
narrower airway calibre. The abnormalities were particularly pronounced in the small airways, as evidenced by the greater differences between the groups in FEF75 compared with FEF50 and FEF25. Comparison of the lung function results of the three groups showed that differences in lung function were most marked between the RSV group and the non-respiratory group, with significant differences in the FEV0.75, FEV0.75/FVC, FEF50 and FEF75. Except for the FEF75 results, there were no significant differences in the lung function results of the RSV group and the other respiratory group. Greater proportions of the other respiratory group had "wheeze ever" and required medications than the RSV group; it is thus tempting to speculate that at least some of the other respiratory group had asthma. Our results demonstrating narrower airway calibre in prematurely born children who had had an RSV infection are consistent with the majority of studies of previously healthy infants who have suffered an RSV lower respiratory tract infection in the first years after birth.1 2 11 16–24 It has, however, been shown that diminished lung function—particularly abnormalities of small airway function—may predispose to symptomatic RSV lower respiratory tract infections in infants born at term.25–27 Our preliminary results also suggest that prematurely born infants who develop a symptomatic RSV lower respiratory tract infection have worse premorbid lung function. 28 It is therefore not certain whether the abnormalities in lung function seen at follow-up are the results of the RSV infection or reflect premorbid abnormal lung function. This requires assessing in a prospective study including serial lung function measurements before and after RSV infection.

Table 6 Baseline lung function results by hospital admission status in the first 2 years

<table>
<thead>
<tr>
<th></th>
<th>RSV (n = 14)</th>
<th>Other respiratory (n = 27)</th>
<th>Non-respiratory (n = 36)</th>
<th>p Value between the three groups</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gestational age weeks</td>
<td>26 (24–31)</td>
<td>27 (24–31)</td>
<td>28 (25–31)</td>
<td>0.449</td>
</tr>
<tr>
<td>Birth weight (g)</td>
<td>820 (650–1826)</td>
<td>1012 (680–1434)</td>
<td>927 (515–1520)</td>
<td>0.552</td>
</tr>
<tr>
<td>Maternal steroids (%)</td>
<td>85</td>
<td>89</td>
<td>78</td>
<td>0.743</td>
</tr>
<tr>
<td>Surfactant (%)</td>
<td>86</td>
<td>85</td>
<td>78</td>
<td>0.733</td>
</tr>
<tr>
<td>IPPV (%)</td>
<td>100</td>
<td>96</td>
<td>97</td>
<td>1.000</td>
</tr>
<tr>
<td>CPAP (%)</td>
<td>86</td>
<td>48</td>
<td>83</td>
<td>0.006</td>
</tr>
<tr>
<td>HFOV (%)</td>
<td>8</td>
<td>12</td>
<td>0</td>
<td>0.086</td>
</tr>
<tr>
<td>Nitric oxide (%)</td>
<td>7</td>
<td>11</td>
<td>3</td>
<td>0.410</td>
</tr>
<tr>
<td>PDA (%)</td>
<td>29</td>
<td>37</td>
<td>33</td>
<td>0.709</td>
</tr>
<tr>
<td>Air leak (%)</td>
<td>14</td>
<td>22</td>
<td>8</td>
<td>0.320</td>
</tr>
<tr>
<td>Postnatal (%)</td>
<td>36</td>
<td>48</td>
<td>29</td>
<td>0.320</td>
</tr>
</tbody>
</table>

*Results are expressed as percentage predicted for height.

CPAP, continuous positive airway pressure; FEF, forced expiratory flow; FEF25, flow at 25% of vital capacity; FEF50, flow at 50% of vital capacity; FEF75, flow at 75% of vital capacity; FEV, forced expiratory volume; FVC, forced vital capacity; HFOV, high frequency oscillatory ventilation; IPPV, intermittent positive pressure ventilation; PDA, patent ductus arteriosus; PEF, peak expiratory flow; RSV, respiratory syncytial virus.

Figure 1 Hospital admissions related to age. Data are plotted as the median number of hospital admissions per child per year in each group; diamonds, RSV-proven; squares, other respiratory; triangles, non-respiratory.

Figure 2 Cost of care of outpatient attendance related to age. Data are presented as median costs per child per year per group; diamonds, RSV-proven; squares, other respiratory; triangles, non-respiratory.
and this may have biased our results. The bronchial hyperreactivity may be explained by atopy, as bronchiolitis may be seen in children if born at term following RSV infection are conflicting.1–2 31–32 It has been suggested that any association between RSV lower respiratory tract infection and bronchial hyperreactivity may be explained by atopy, as children admitted to hospital with an RSV infection were more likely to be atopic.29 In three studies,1 2 3 31 however, atopy was not more common in the RSV group. In this study we found no significant difference between the RSV and non-RSV groups in the proportions of children with a family history of atopy, but eczema tended to be more common in the RSV group. The relevance of the latter finding is unclear. Studies assessing allergic sensitisation following RSV infection have yielded conflicting results.1–5 31–32 Unfortunately, few agreed to skin prick testing in this study, so we are unable to determine whether RSV infection is associated with increased allergic sensitisation in prematurely born children.

In conclusion, in all three groups, healthcare utilisation and related cost of care decreased with increasing age. Those who were hospitalised with RSV in the first 2 years after birth, however, had more outpatient attendances and a greater related cost of care between the ages of 5–7 inclusive and worse lung function than children not admitted in the first 2 years for a respiratory cause. Whether these results reflect worse premorbid lung function in premature born children admitted to hospital with an RSV infection merits testing. It would also be important to assess in a randomised trial whether RSV preventive therapy reduced healthcare utilisation at follow-up.

Funding: The research nurses were funded by Abbott Laboratories Ltd and Medimmune.

Competing interests: Abbott Laboratories market palivizumab, a monoclonal antibody for prophylaxis against RSV. AG, WI, and PC have received honoraria for speaking at Abbott sponsored conferences. TL and JB are employees of Abbott Laboratories. TL was the clinical monitor and JB was the clinical project manager for this study.

Ethics approval: The study was approved by the local research ethics committees of the four hospitals.

REFERENCES

School age outcome of hospitalisation with respiratory syncytial virus infection of prematurely born infants


Thorax 2009 64: 490-495 originally published online February 12, 2009
doi: 10.1136/thx.2008.095547

Updated information and services can be found at:
http://thorax.bmj.com/content/64/6/490

These include:

References
This article cites 31 articles, 16 of which you can access for free at:
http://thorax.bmj.com/content/64/6/490#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

Child health (843)
TB and other respiratory infections (1273)
Infant health (48)
Airway biology (1100)
Bronchopulmonary dysplasia (16)
Epidemiologic studies (1829)
Lung function (773)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/